<DOC>
	<DOC>NCT00979316</DOC>
	<brief_summary>The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).</brief_summary>
	<brief_title>Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Body Mass Index (BMI) of 18 to 32 kg/mÂ², inclusive. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men, ages 18 to 55 Healthy subjects History of cardiac arrhythmias or palpitations associated with presyncope or syncope, or history of unexplained syncope Sexually active fertile men not using effective birth control (double barrier) if their partners are WOCBP Women who are pregnant or breastfeeding History of allergy or intolerance to moxifloxacin or any member of the quinolone class of antimicrobial agents History of hypokalemia, history or family history of prolonged QT interval, or family history of sudden cardiac death at a young age Any clinically significant ECG abnormality History of seizure disorders History of drowning survival</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>